Publicacións (173) Publicacións nas que participase algún/ha investigador/a

2023

  1. 1278P ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain

    Annals of Oncology

  2. 1793P PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase

    Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)

  3. 1995P Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study

    Annals of Oncology, Vol. 34, pp. S1064-S1065

  4. 2083P Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort

    Annals of Oncology, Vol. 34, pp. S1096

  5. 2149P Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO)

    Annals of Oncology

  6. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  7. Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials

    World Conference on Lung Cancer

  8. Erratum: Personalized Precision Medicine for Health Care Professionals: Development of a Competency Framework (JMIR Medical Education (2023) 9 (e43656) DOI: 10.2196/43656)

    JMIR Medical Education

  9. Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

    Clinical and Translational Oncology, Vol. 25, Núm. 10, pp. 3021-3031

  10. MA16.04 Circulating Tumor DNA Quantification by NGS Should Be Adapted to the Methodology Used

    Meeting Abstract

  11. P-277 Real-world efficacy, safety, and impact of the GIPI score of nivolumab in advanced esophageal squamous cell carcinoma (ESCC) refractory or intolerant to prior chemotherapy in European population: The EPIC trial

    25th World Congress on Gastrointestinal Cancer

  12. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

    Journal of Clinical Medicine, Vol. 12, Núm. 15

  13. Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC

    Meeting Abstract

  14. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

  15. Personalized Precision Medicine for Health Care Professionals: Development of a Competency Framework

    JMIR Medical Education, Vol. 9